Edrophonium
Enlon, Reversol, Tensilon (edrophonium) is a small molecule pharmaceutical. Edrophonium was first approved as Tensilon on 1982-01-01. It is used to treat drug-induced abnormalities in the USA. It is known to target acetylcholinesterase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hereditary congenital and neonatal diseases and abnormalities | D009358 |
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Atropine sulfate
+
Edrophonium chloride
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| enlon | 2006-10-17 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| drug-induced abnormalities | — | D000014 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | — | 1 | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Ischemia | D007511 | EFO_0000556 | 1 | — | 1 | — | — | 2 | |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | 1 | 1 | — | — | 2 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | D46 | 2 | 1 | — | — | — | 2 | |
| Lymphoma | D008223 | C85.9 | 2 | 2 | — | — | — | 2 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | — | 1 | |
| Castration-resistant prostatic neoplasms | D064129 | — | 1 | — | — | — | 1 | ||
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 1 | — | — | — | 1 |
| Adenocarcinoma | D000230 | — | 1 | — | — | — | 1 | ||
| Headache | D006261 | HP_0002315 | R51 | 1 | 1 | — | — | — | 1 |
| Arthralgia | D018771 | HP_0002829 | M25.5 | 1 | 1 | — | — | — | 1 |
| Hyperpigmentation | D017495 | 1 | 1 | — | — | — | 1 | ||
| Non-hodgkin lymphoma | D008228 | C85.9 | 1 | 1 | — | — | — | 1 |
Show 8 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 | ||
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Peripheral arterial disease | D058729 | EFO_0004265 | 1 | — | — | — | — | 1 | |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | — | — | 2 | 2 | ||
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Liver failure | D017093 | HP_0001399 | K72.9 | — | — | — | — | 1 | 1 |
| Urologic diseases | D014570 | N39.9 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | EDROPHONIUM |
| INN | edrophonium chloride |
| Description | Edrophonium is a quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals. It has a role as an EC 3.1.1.8 (cholinesterase) inhibitor, a diagnostic agent and an antidote. It is a quaternary ammonium ion and a member of phenols. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; quaternary ammonium derivatives |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC[N+](C)(C)c1cccc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 312-48-1 |
| RxCUI | 3752 |
| ChEMBL ID | CHEMBL1104 |
| ChEBI ID | 251408 |
| PubChem CID | 3202 |
| DrugBank | DB01010 |
| UNII ID | QO611KSM5P (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,960 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
114 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more